RiteMED
RiteMED is a Philippine branded generic pharmaceutical company, founded in 2002, selling affordable generic medicines across cardiovascular, diabetes, antibiotic, pain, and respiratory categories through nationwide pharmacy chains and e-commerce platforms.
- Company typePrivate
- Founded2002
- HeadquartersMandaluyong, Philippines
- Headcount501–1,000
- GTM typeB2C
- OfferingHardware or Manufacturing
What RiteMED does
RiteMED is a Philippine pharmaceutical company founded in 2002 and headquartered in Mandaluyong City. The company manufactures and distributes branded generic medicines across a broad therapeutic portfolio, including cardiovascular agents (Losartan, Valsartan, Amlodipine, Metoprolol), diabetes treatments (Metformin, insulin, Pioglitazone), anti-infectives (Cefaclor, Meropenem, Linezolid), NSAIDs and analgesics (Ibuprofen, Meloxicam, Diclofenac, Paracetamol, Mefenamic Acid), gastrointestinal drugs (Lansoprazole, Domperidone), respiratory and allergy products (Montelukast, Ambroxol, Loratadine), dermatologicals (Terbinafine, Tolnaftate), vitamins and supplements, and home remedies. Product pricing is positioned for mass-market affordability, with most maintenance SKUs under ₱100 and a range from ₱2.25 to ₱4,144 across the catalog.
RiteMED sells primarily through third-party retail pharmacy chains — Mercury Drug, Southstar Drug, Rose Pharmacy, and Watsons — and through e-commerce channels Lazada, Shopee, and MedExpress, giving it nationwide single-country (Philippines) distribution. The company's go-to-market combines celebrity brand ambassadorships (Coco Martin, Charo Santos-Concio on a renewed 7-year partnership), community medical missions, and content marketing through a health-information portal with articles, videos, and symptom checkers. Its core technology is generic pharmaceutical manufacturing and distribution; there is no disclosed proprietary technology, AI capability, or platform architecture beyond standard e-commerce storefronts and digital utility tools (pharmacy locator, gamot calculator).
The revenue model is straightforward unit-pricing sales of branded generic medicines to mass-market Filipino consumers through retail and online intermediaries, supplemented by CSR-driven donations and physician-engagement programs that reinforce prescription pull-through. Customer segments are horizontal: general Filipino consumers seeking affordable medicines, healthcare providers who prescribe or recommend the products, and two focused verticals — senior citizens (maintenance drugs) and pediatric patients (RiteMED for Kids line). Ownership is private and not publicly disclosed, with 501–1,000 employees and no known parent company or external funding rounds in the source data.
RiteMED firmographics
Firmographics- Name
- RiteMED
- Legal name
- RiteMED
- Website
- https://ritemed.com.ph
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- RiteMED is a Philippine branded generic pharmaceutical company, founded in 2002, selling affordable generic medicines across cardiovascular, diabetes, antibiotic, pain, and respiratory categories through nationwide pharmacy chains and e-commerce platforms.
- Ownership category
- akta.pro rank
RiteMED industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Specialty Pharmaceutical Distributors (HLAIAJAB), Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where RiteMED is headquartered
LocationHeadquarters
- HQ city
- Mandaluyong
- HQ country
- Philippines
- HQ region
- Asia
Offices1 record
Markets served
RiteMED business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Branded Generic Medicines Sales: RiteMED generates revenue through the sale of branded generic medicines across multiple therapeutic categories including cardiovascular, diabetes, antibiotics, pain management, respiratory, and dermatological products. Products are sold through retail pharmacies, drugstores, and online marketplaces in the Philippines.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Budget-friendly generic medications |
Go-to-market motion2 records
Distribution channels7 records
Marketing channels5 records
RiteMED product offering
Product offeringCore offering
RiteMED manufactures and distributes branded generic pharmaceutical products in the Philippines across major therapeutic categories including cardiovascular, antidiabetic, antibiotic, analgesic, antipyretic, mucolytic, and dermatological treatments. The company offers prescription and over-the-counter medicines bearing the "RM" brand prefix and sells them through national pharmacy chains and major e-commerce platforms.
Product overview
RiteMED is a Philippine pharmaceutical company offering a comprehensive portfolio of branded generic medicines positioned as affordable, high-quality alternatives. The product portfolio spans multiple therapeutic categories including cardiovascular medications (RM Metoprolol Tartrate, RM Losartan, RM Valsartan, RM Amlodipine, RM Simvastatin), diabetes management (RM Metformin, RM Insulyf insulin, RM Pioglitazone), anti-infectives (RM Cefaclor, RM Meropenem, RM Linezolid, RM Doxycycline, RM Metronidazole), pain and arthritis treatments (RM Ibuprofen, RM Meloxicam, RM Diclofenac Sodium, RM Mefenamic Acid), gastrointestinal medications (RM Lansoprazole, RM Domperidone, RM Hyoscine), respiratory/allergy products (RM Montelukast, RM Ambroxol, RM Loratadine), dermatologicals (RM Terbinafine, RM Tolnaftate), vitamins and supplements (RM Vitamin B Complex, RM Ascorbic Acid), kidney supplements (RM Remoston/Sambong), and home remedies (RM Isopropyl Alcohol). The company distributes through retail pharmacies nationwide including Mercury Drug, Southstar Drug, Rose Pharmacy, Watsons, and online platforms such as Lazada and Shopee.
Differentiator
Problem solved
Functional benefit
Products and services
- RM Acyclovir
- RM Ambroxol
- RM Ascorbic Acid
- RM Carbocisteine
- RM Cefalexin
- RM Ibuprofen
- RM Metoprolol
Quantifiable outcome
- 23 years of operation in the Philippine pharmaceutical market
- +1 more outcomes
Companies that use RiteMED
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
RiteMED technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
RiteMED partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Charo Santos-ConciocoreCharo Santos-Concio has maintained a 7-year partnership with RiteMED as brand ambassador, championing the cause of accessible, high-quality, and affordable medicines for Filipino families. The partnership was renewed in September 2025.
- Coco MartincoreCoco Martin serves as RiteMED's brand ambassador, supporting the company's advocacy 'Gusto Namin Gumaling Kayo' (We Want You to Get Better). His involvement includes participation in medical missions and community health outreach programs to promote accessible, affordable medicines to Filipino families.
- Manila City Government / Mayor Francisco 'Isko' Moreno DomagosominorRiteMED donated ₱1.1 million worth of maintenance medicines to senior citizens of Manila. The city government, through Mayor Domagoso, officially accepted the donation, demonstrating community partnership for healthcare access.
- Diosdado P. Macapagal Elementary School, Brgy. Tatalon, Quezon CityminorSite of RiteMED's 23rd anniversary mega medical mission in partnership with brand ambassador Coco Martin, providing healthcare support to local community members.
- Philippine College of Physicians (PCP)minorRiteMED participated in the 55th PCP Annual Convention held May 4-7, 2025 at SMX Convention Center, showcasing products and educational materials to internists, diplomates, and physicians to reinforce advocacy for quality, accessible medicines among the medical community.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
RiteMED competitors and assessment
Company assessmentEmerging players
- Glenmark Pharmaceuticals: Indian-headquartered generic and specialty pharma with established Philippines operations, offering branded generics in respiratory, dermatology, and cardiovascular. Direct regional competitor to RiteMED in the Philippine market.
Direct peers
- Unilab (United Laboratories Inc.): The largest pharmaceutical company in the Philippines, offering a broad portfolio of branded generics and OTC products across similar therapeutic categories. Unilab is RiteMED's closest direct competitor, commanding dominant retail pharmacy share in the same channels.
- Pascual Laboratories (Pascual Consumer Healthcare): A major Philippine pharmaceutical manufacturer and marketer of branded generics, vitamins, and OTC products. Comparable in scale and channel strategy, serving the same Filipino consumer base through retail pharmacy distribution.
Broad incumbents
- Cipla: Major Indian generic pharmaceutical manufacturer with strong emerging markets focus, exporting to the Philippines and other Southeast Asian countries across respiratory, anti-infectives, and cardiovascular generics.
- Teva Pharmaceutical Industries: The world's largest generic drug manufacturer with a broad finished dosage form portfolio spanning cardiovascular, anti-infectives, CNS, and respiratory categories. While not focused on the Philippine mass market, it competes in the same generic molecules RiteMED sells.
- Viatris: Global healthcare company formed from Mylan and Upjohn, with one of the world's largest generic medicine portfolios and significant emerging-market presence. Competes with RiteMED in generics across cardiovascular, anti-infectives, and other categories.
- Stada Arzneimittel: European-based generics and consumer healthcare company with growing presence in emerging markets, including Southeast Asia. Comparable in branded generic strategy and therapeutic category coverage.
- Lupin Pharmaceuticals: Major Indian generic pharmaceutical company with strengths in cardiovascular, diabetes, and anti-infectives generics. Exports into the Philippines and Southeast Asia with comparable molecule coverage to RiteMED.
- Sandoz: The generic pharmaceuticals division of Novartis, a global leader in generic and biosimilar medicines. Operates across the same small-molecule generic categories as RiteMED with global manufacturing scale.
- Aurobindo Pharma: One of India's largest generic manufacturers with a broad finished dosage form portfolio across antibiotics, cardiovascular, and CNS. Active exporter to the Philippines and competing in the same generic categories.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
RiteMED social profiles
Digital presenceRiteMED financial estimates
Financial estimateRevenue estimate
Valuation estimate
RiteMED leadership team
Management profileNumber of profiles
RiteMED funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RiteMED M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RiteMED
What does RiteMED do?
RiteMED manufactures and distributes branded generic pharmaceutical products in the Philippines across major therapeutic categories including cardiovascular, antidiabetic, antibiotic, analgesic, antipyretic, mucolytic, and dermatological treatments. The company offers prescription and over-the-counter medicines bearing the "RM" brand prefix and sells them through national pharmacy chains and major e-commerce platforms.
When was RiteMED founded?
RiteMED was founded in 2002. It employs 501 to 1,000 people.
Where is RiteMED based?
RiteMED is headquartered in Mandaluyong, Philippines, in the Asia region.
How does RiteMED make money?
One revenue line is on record: branded Generic Medicines Sales.
Who are RiteMED's main competitors?
Glenmark Pharmaceuticals is listed as an emerging player. Direct peers are Unilab (United Laboratories Inc.) and Pascual Laboratories (Pascual Consumer Healthcare). Broad incumbents are Cipla, Teva Pharmaceutical Industries, Viatris, Stada Arzneimittel, Lupin Pharmaceuticals, Sandoz and Aurobindo Pharma.
Does RiteMED have an API?
No public API is recorded for RiteMED.
What industry is RiteMED in?
RiteMED's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.